UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 SCPHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 46-5184075 (State or other jurisdiction of in ...

BURLINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) – scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the first quarter ended March 31, 2024, and provided a business update. Business Update • For the first quarter ended March 31, 2024, scPharmaceuticals reports: • Net FUROSCIX revenue of ...

scPharmaceuticals Inc (NASDAQ:SCPH) Q4 2023 Results Conference Call March 13, 2024 4:30 PM ET Company Participants PJ Kelleher - LifeSci Advisors John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President, Commercial Rachael Nokes - Chief Financial Officer John Mohr - Senior Vice President of Clinical Development & Medical Affairs Conference Call Participants Rosa Chen - Leerink Partners Stacy Ku - TD Cowen Douglas Tsao - H. C. Wainwright Chase Knickerbocker - Craig-Hallum Naz Rahman - Maxi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the transition period from to Washington, D.C. 20549 Commission File Number 001-38293 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 SCPHARMACEUTICALS INC. (Exact name of registrant as specified in its Charter) (State or other jurisdiction of incorporation or ...

scPharmaceuticals Inc (NASDAQ:SCPH) Q3 2023 Earnings Call Transcript November 8, 2023 4:30 PM ET Company Participants PJ Kelleher - LifeSci Advisors John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President, Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Nik Gasic - Leerink Partners Douglas Tsao - H.C. Wainwright Naz Rahman - Maxim Group Chase Knickerbocker - Craig-Hallum Capital Group Operator Thank you for standing by. This is the conference operator. Wel ...

NSIDEOUT Innovative outpatient solutions that bring care closer to home Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company is responsible for the accuracy of these statements and believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 Delaware 46-5184075 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 25 Burli ...

scPharmaceuticals Inc. (NASDAQ:SCPH) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants PJ Kelleher - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President, Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Glen Santangelo - Jefferies Stacy Ku - TD Cowen Doug Tsao - H.C. Wainwright Naz Rahman - Maxim Group Operator Good day and welcome to the scPharmaceuticals Second Quarter 2023 Earnings Conference Call. Al ...

1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 SCPHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 46-5184075 (State or other jurisdiction of ( ...

1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 SCPHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 46-5184075 (State or other jurisdiction of ...